Weiss Asset Management LP 13D and 13G filings for Theravance Biopharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-03-05 09:01 am Unchanged |
2024-03-01 | 13D | Theravance Biopharma, Inc. TBPH |
Weiss Asset Management LP | 7,457,060 15.500% |
0 (Unchanged) |
Filing |
| 2023-08-14 5:05 pm Unchanged |
2023-08-09 | 13D | Theravance Biopharma, Inc. TBPH |
Weiss Asset Management LP | 7,457,060 14.120% |
0 (Unchanged) |
Filing |
| 2023-04-12 1:51 pm Unchanged |
2023-04-11 | 13D | Theravance Biopharma, Inc. TBPH |
Weiss Asset Management LP | 7,457,060 11.790% |
0 (Unchanged) |
Filing |
| 2023-02-10 4:05 pm Purchase |
2022-12-31 | 13G | Theravance Biopharma, Inc. TBPH |
Weiss Asset Management LP | 7,457,060 11.090% |
1,299,700 (+21.11%) |
Filing |
| 2023-02-10 3:09 pm Purchase |
2022-12-31 | 13G | Theravance Biopharma, Inc. TBPH |
Weiss Asset Management LP | 7,457,060 11.090% |
7,457,060 (New Position) |
Filing |
| 2022-06-16 3:41 pm Purchase |
2022-06-08 | 13G | Theravance Biopharma, Inc. TBPH |
Weiss Asset Management LP | 6,157,360 8.090% |
6,157,360 (New Position) |
Filing |